1. Home
  2. NSRX vs GRML Comparison

NSRX vs GRML Comparison

Compare NSRX & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nasus Pharma Ltd. Ordinary Shares

NSRX

Nasus Pharma Ltd. Ordinary Shares

HOLD

Current Price

$3.08

Market Cap

38.9M

Sector

Health Care

ML Signal

HOLD

Logo Greenland Mines Ltd. Common Stock

GRML

Greenland Mines Ltd. Common Stock

N/A

Current Price

$0.25

Market Cap

34.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NSRX
GRML
Founded
2019
N/A
Country
Israel
United States
Employees
7
5
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.9M
34.9M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
NSRX
GRML
Price
$3.08
$0.25
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$19.67
N/A
AVG Volume (30 Days)
20.6K
3.4M
Earning Date
03-25-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.98
$0.21
52 Week High
$9.99
$0.55

Technical Indicators

Market Signals
Indicator
NSRX
GRML
Relative Strength Index (RSI) 43.46 42.58
Support Level $2.78 $0.21
Resistance Level $3.58 $0.34
Average True Range (ATR) 0.22 0.03
MACD -0.05 0.00
Stochastic Oscillator 0.00 41.41

Price Performance

Historical Comparison
NSRX
GRML

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

About GRML Greenland Mines Ltd. Common Stock

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

Share on Social Networks: